

Sheppard Mullin Advises Tharimmune, Inc. in \$540 Million Private Placement

11.03.2025

Sheppard Mullin is representing Tharimmune, Inc. (NASDAQ: THAR), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory and oncologic conditions, in its approximately \$540 million private placement.

The financing is led by new investors DRW and Liberty City Ventures, with participation from several leading institutional and accredited investors. Tharimmune intends to use the net proceeds from the private placement to acquire Canton Coin, a utility token designed to support interoperability and settlement across the Canton Network, and for working capital and general corporate purposes. The transaction supports Tharimmune's strategy to become a Super Validator and to build applications facilitating institutional adoption of blockchain-based capital markets solutions.

The deal is led by partner and co-leader of the firm's Life Sciences team Jeff Fessler and special counsel Greg Carney.

[Click here to read more.](#)

Attorneys

Greg R. Carney

Jeffrey J. Fessler

Practice Areas

Capital Markets

Corporate

Industries

Life Sciences